Travere Therapeutics (TVTX) Shares Outstanding (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Shares Outstanding (Entity) came in at $92.4 million in Q1 2026, up 4.07% YoY from $88.8 million in Q1 2025, and up 1.63% on a QoQ basis from $90.9 million in Q4 2025.
Travere Therapeutics (TVTX) Shares Outstanding (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Shares Outstanding (Entity) data on file, last reported at $92.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 4.07% year-over-year to $92.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.4 million (up 4.07% YoY) and the FY2025 annual result came in at $90.9 million, up 3.97% from the prior year.
- Shares Outstanding (Entity) improved to $92.4 million in Q1 2026, from $90.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $92.4 million in Q1 2026 to a low of $63.5 million in Q1 2022.
- A 5-year average of $77.9 million and a median of $76.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 17.44% — and 2024, when it rose 1.98%.
- Tracing TVTX's Shares Outstanding (Entity) over 5 years: stood at $64.3 million in 2022, then climbed by 17.23% to $75.4 million in 2023, then increased by 16.04% to $87.5 million in 2024, then climbed by 3.97% to $90.9 million in 2025, then rose by 1.63% to $92.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $92.4 million (Q1 2026), $90.9 million (Q4 2025), and $89.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 93.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.87 Mn |
| Mar 31, 2026 | 91.87 Mn |
| Dec 31, 2025 | 89.21 Mn |
| Sep 30, 2025 | 89.23 Mn |
| Jun 30, 2025 | 88.95 Mn |
| Mar 31, 2025 | 88.36 Mn |
| Dec 31, 2024 | 78.89 Mn |
| Sep 30, 2024 | 77.78 Mn |
| Jun 30, 2024 | 77.50 Mn |
| Mar 31, 2024 | 77.14 Mn |
| Dec 31, 2023 | 74.27 Mn |
| Sep 30, 2023 | 76.31 Mn |
| Jun 30, 2023 | 76.00 Mn |
| Mar 31, 2023 | 68.17 Mn |
| Dec 31, 2022 | 63.76 Mn |
| Sep 30, 2022 | 64.03 Mn |
| Jun 30, 2022 | 63.64 Mn |
| Mar 31, 2022 | 63.13 Mn |
| Dec 31, 2021 | 59.83 Mn |
| Sep 30, 2021 | 60.80 Mn |